Targeted therapies in pancreatic cancer: Promises and failures. Issue 3 (9th December 2018)

• Record Type: Journal Article
• Authors: Barati Bagherabad, Matineh; Afzaljavan, Fahimeh; ShahidSales, Soodabeh; Hassanian, Seyed Mahdi; Avan, Amir
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 3(2019)
• Page Start: 2726
• Page End: 2741
• Publication Date: 2018-12-09
• Subjects: chemoresistance -- detection -- pancreatic cancer -- prevention -- treatment; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.26284
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an incidence rate nearly equal to its mortality rate. The poor prognosis of the disease can be explained by the absence of effective biomarkers for screening and early detection, together with the aggressive behavior and resistance to the currently available chemotherapy. The therapeutic failure can also be attributed to the inter‐/intratumor genetic heterogeneity and the abundance of tumor stroma that occupies the majority of the tumor mass. Gemcitabine is used in the treatment of PDAC; however, the response rate is less than 12%. A recent phase III trial revealed that the combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin could be an option for the treatment of metastatic PDAC patients with good performance status, although these approaches can result in high toxicity level. Further investigations are required to develop innovative anticancer agents that either improve gemcitabine activity, within novel combinatorial approaches or acts with a better efficacy than gemcitabine. The aim of the current review is to give an overview of preclinical and clinical studies targeting key dysregulated signaling pathways in PDAC.